Switching from inhaled iloprost to selexipag pill for pulmonary hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This study looks at how patients feel and how well they stick to treatment when switching from an inhaled medication (iloprost) to a pill (selexipag) for pulmonary arterial hypertension (high blood pressure in the lungs). If you are already switching, your experiences can help doctors understand the benefits and challenges of this change.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have pulmonary arterial hypertension (PAH)—a type of high blood pressure in the lungs—confirmed by a heart test.
- You have been using inhaled iloprost (Ventavis) as part of your regular care.
- Your doctor has decided to switch you from inhaled iloprost to the pill selexipag (Uptravi).
- You are able to answer questionnaires about how you feel and give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether switching from the oral medicine selexipag to an inhaled medicine called treprostinil can improve symptoms or side effects in people with pulmonary arterial hypertension (PAH). It may be an option if you are not getting enough benefit or are having trouble tolerating selexipag.
This study looks at the long-term effects of a medicine called selexipag on people with pulmonary hypertension caused by schistosomiasis, a parasitic infection. It aims to see if selexipag improves outcomes compared to standard care.
This study compares two approaches for people with PAH whose current treatment (a combination of sildenafil and an endothelin receptor antagonist) needs to be stepped up. Half the participants will add a third medicine (iloprost or selexipag), while the other half will increase their sildenafil dose. The goal is to see which strategy works better for improving symptoms and lowering risk.
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
This study tests if a smartphone app can help people with pulmonary arterial hypertension (PAH) stick to their inhaled iloprost treatment. It is for adults already on this treatment at a specific clinic in Brazil.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.